2022
2021
2020
2019
2018
2017
2016
2015
2014
1
2
→
Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
Dec 11, 2018
Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
Dec 7, 2018
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
Nov 19, 2018
Tenax Therapeutics to Present at Upcoming Investor Conferences
Sep 20, 2018
Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
Aug 29, 2018
Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients
Aug 28, 2018
Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO
Jun 5, 2018
Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients
Jun 1, 2018
Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients
Apr 4, 2018
Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mar 14, 2018